AR067662A1 - Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. - Google Patents
Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso.Info
- Publication number
- AR067662A1 AR067662A1 ARP080103200A ARP080103200A AR067662A1 AR 067662 A1 AR067662 A1 AR 067662A1 AR P080103200 A ARP080103200 A AR P080103200A AR P080103200 A ARP080103200 A AR P080103200A AR 067662 A1 AR067662 A1 AR 067662A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- diseases
- aryl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 210000000653 nervous system Anatomy 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- -1 halobenzenesulfonyl Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas que los contienen, y su utilizacion como medicamentos. Los compuestos de formula general (1) poseen una elevada afinidad por los receptores D3 de la dopamina y 5-HT2A de la serotonina (5- hidroxitriptamina; 5-HT) y son efectivos en el tratamiento de trastornos psicoticos, así como otras enfermedades como la depresion y ansiedad, dependencia de fármacos, demencias y deterioro de la memoria. Reivindicacion 1: Un compuesto de formula (1) en el que: X es independientemente halogeno, ciano; alquiloC1-6, alcoxi C1-6 o haloalquilo C1-6: n es 0, 1, 2 o 3; R1 es H o alquilo C1-6; R2 es como en los restos de formulas (2); R3 es hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, cicloalquilo C3-10, arilo, heterocicloalquilo de 4 a 10 miembros, o heteroarilo de 5 a 10 miembros, que están opcionalmente sustituidos por uno a cinco sustituyentes seleccionados del grupo que consiste en: halo, ciano, -SO2-alquilo C1-6, hidroxilo, alquilo C1-6, haloalquilo C1-6, -CO(O)-alquilo C1-6, alcoxi C1-6 opcionalmente sustituido por uno o más Ra, cicloalquilo C3-10 opcionalmente sustituido por uno o más Ra, heterocicloalquilo de 4 a 10 miembros opcionalmente sustituido por uno o más Ra; arilo opcionalmente sustituido por uno o más Ra, heteroarilo de 5 a 10 miembros opcionalmente sustituido por uno o más Ra, y -NRbRc, en el que Rb es H o alquilo C1-6 y en el que Rc es H, alquilo C1-6 o arilo opcionalmente sustituido por uno o más Ra; en el que Ra se selecciona a partir de: halo, ciano, oxo, hidroxilo, halobencenosulfonilo, alquilo C1-6, haloalquilo C1-6, -NH(CO)-alquilo C1-6, dialquilamino C1-6, -O(CO)-alquilo C1-6, alquilsulfonilo C1-6, alcoxi C1-6, haloalcoxi C1-6, heterocicloalquilo de 4 a 10 miembros, arilo, ariloxi, o heteroarilo de 5 a 10 miembros; así como las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113252 | 2007-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067662A1 true AR067662A1 (es) | 2009-10-21 |
Family
ID=40281888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103200A AR067662A1 (es) | 2007-07-26 | 2008-07-24 | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20090029977A1 (es) |
| EP (1) | EP2183245B1 (es) |
| JP (1) | JP5502733B2 (es) |
| KR (1) | KR101169518B1 (es) |
| CN (1) | CN101778844B (es) |
| AR (1) | AR067662A1 (es) |
| AU (1) | AU2008280187B2 (es) |
| BR (1) | BRPI0815092A2 (es) |
| CA (1) | CA2694009A1 (es) |
| CL (1) | CL2008002162A1 (es) |
| ES (1) | ES2498673T3 (es) |
| PE (1) | PE20090892A1 (es) |
| RU (1) | RU2480466C2 (es) |
| TW (1) | TWI363623B (es) |
| WO (1) | WO2009013212A2 (es) |
| ZA (1) | ZA201000354B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2396265C2 (ru) * | 2006-02-17 | 2010-08-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3 |
| ES2402875T3 (es) * | 2008-09-22 | 2013-05-10 | F. Hoffmann-La Roche Ag | Moduladores de receptores de D3 y de 5-HT2a |
| CA2737252A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors |
| US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8877778B2 (en) * | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8722683B2 (en) * | 2011-02-17 | 2014-05-13 | Hoffmann La-Roche Inc. | Benzodioxole piperazine compounds |
| US8598357B2 (en) * | 2011-03-03 | 2013-12-03 | Hoffmann-La Roche Inc. | Benzodioxole piperidine compounds |
| US8921397B2 (en) * | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| CN105367565B (zh) * | 2014-08-20 | 2018-10-02 | 上海医药工业研究院 | 哌嗪(啶)环己基衍生物及其治疗精神神经疾病的应用 |
| CN106518841B (zh) * | 2015-09-15 | 2019-03-05 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
| WO2017045599A1 (zh) * | 2015-09-15 | 2017-03-23 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| KR20200112910A (ko) | 2018-01-26 | 2020-10-05 | 시오노기 앤드 컴파니, 리미티드 | 도파민 d3 수용체 길항 작용을 갖는 축환 화합물 |
| WO2019146740A1 (ja) * | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| CN118772126A (zh) | 2019-10-29 | 2024-10-15 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
| TW202118758A (zh) * | 2019-11-05 | 2021-05-16 | 大陸商上海翰森生物醫藥科技有限公司 | 苯并噻吩類衍生物調節劑、其製備方法和應用 |
| BR112022021228A2 (pt) * | 2020-04-26 | 2022-12-06 | Jiangsu Nhwa Pharmaceutical Co Ltd | Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo |
| AU2022266937A1 (en) | 2021-04-28 | 2023-10-19 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| DK60693D0 (da) * | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Kemiske forbindelser, deres fremstilling og anvendelse |
| WO1998034933A1 (en) | 1997-02-07 | 1998-08-13 | Hoechst Marion Roussel, Inc. | (4-piperidinyl)-1h-2-benzopyran derivatives useful as antipsychotic agents |
| US6335326B1 (en) * | 1998-02-09 | 2002-01-01 | Duphar International Research B.V. | Benzisoxazole derivatives having d4-antagonistic activity |
| DE10010612A1 (de) * | 2000-03-03 | 2001-09-27 | Merck Patent Gmbh | Verwendung von PDE V-Inhibitoren |
| ATE412638T1 (de) | 2001-02-16 | 2008-11-15 | Aventis Pharma Inc | Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden |
| GB0117950D0 (en) | 2001-02-16 | 2001-09-19 | Aventis Pharma Inc | Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands |
| EP1361875A2 (en) | 2001-02-16 | 2003-11-19 | Aventis Pharmaceuticals Inc. | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| GB0117577D0 (en) * | 2001-02-16 | 2001-09-12 | Aventis Pharm Prod Inc | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands |
| RU2396265C2 (ru) * | 2006-02-17 | 2010-08-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3 |
| EP2079693B1 (en) * | 2006-10-31 | 2013-02-27 | F. Hoffmann-La Roche AG | Ether derivatives dual modulators of the 5-ht2a and d3 receptors |
| BRPI0814999A2 (pt) * | 2007-08-09 | 2015-02-03 | Hoffmann La Roche | Derivados de bezoil-piperidina como moduladores duais dos receptores 5-ht2a e d3 |
| ES2402875T3 (es) * | 2008-09-22 | 2013-05-10 | F. Hoffmann-La Roche Ag | Moduladores de receptores de D3 y de 5-HT2a |
| ES2643613T3 (es) * | 2010-08-17 | 2017-11-23 | The Procter & Gamble Company | Detergentes para el lavado de vajillas a mano sostenibles y estables |
| US8877778B2 (en) * | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
-
2008
- 2008-07-17 CA CA2694009A patent/CA2694009A1/en not_active Abandoned
- 2008-07-17 CN CN2008800255361A patent/CN101778844B/zh not_active Expired - Fee Related
- 2008-07-17 KR KR1020107004201A patent/KR101169518B1/ko not_active Expired - Fee Related
- 2008-07-17 BR BRPI0815092-3A2A patent/BRPI0815092A2/pt not_active IP Right Cessation
- 2008-07-17 WO PCT/EP2008/059356 patent/WO2009013212A2/en not_active Ceased
- 2008-07-17 JP JP2010517368A patent/JP5502733B2/ja not_active Expired - Fee Related
- 2008-07-17 EP EP08775170.7A patent/EP2183245B1/en not_active Not-in-force
- 2008-07-17 ES ES08775170.7T patent/ES2498673T3/es active Active
- 2008-07-17 AU AU2008280187A patent/AU2008280187B2/en not_active Ceased
- 2008-07-17 RU RU2010104631/04A patent/RU2480466C2/ru not_active IP Right Cessation
- 2008-07-18 US US12/175,476 patent/US20090029977A1/en not_active Abandoned
- 2008-07-23 PE PE2008001250A patent/PE20090892A1/es not_active Application Discontinuation
- 2008-07-24 CL CL2008002162A patent/CL2008002162A1/es unknown
- 2008-07-24 AR ARP080103200A patent/AR067662A1/es not_active Application Discontinuation
- 2008-07-25 TW TW097128485A patent/TWI363623B/zh not_active IP Right Cessation
-
2010
- 2010-01-18 ZA ZA201000354A patent/ZA201000354B/xx unknown
-
2011
- 2011-10-25 US US13/280,523 patent/US20120040972A1/en not_active Abandoned
-
2013
- 2013-02-21 US US13/772,390 patent/US8829029B2/en not_active Expired - Fee Related
-
2014
- 2014-07-24 US US14/340,093 patent/US20140350051A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2498673T3 (es) | 2014-09-25 |
| EP2183245A2 (en) | 2010-05-12 |
| BRPI0815092A2 (pt) | 2015-02-03 |
| PE20090892A1 (es) | 2009-07-13 |
| CL2008002162A1 (es) | 2009-05-29 |
| JP2010534632A (ja) | 2010-11-11 |
| WO2009013212A3 (en) | 2009-06-11 |
| KR101169518B1 (ko) | 2012-07-27 |
| US8829029B2 (en) | 2014-09-09 |
| CA2694009A1 (en) | 2009-01-29 |
| RU2480466C2 (ru) | 2013-04-27 |
| AU2008280187A1 (en) | 2009-01-29 |
| CN101778844B (zh) | 2013-01-02 |
| TWI363623B (en) | 2012-05-11 |
| EP2183245B1 (en) | 2014-07-09 |
| US20140350051A1 (en) | 2014-11-27 |
| WO2009013212A2 (en) | 2009-01-29 |
| KR20100036384A (ko) | 2010-04-07 |
| CN101778844A (zh) | 2010-07-14 |
| AU2008280187B2 (en) | 2013-05-16 |
| TW200911236A (en) | 2009-03-16 |
| US20090029977A1 (en) | 2009-01-29 |
| US20130165432A1 (en) | 2013-06-27 |
| ZA201000354B (en) | 2010-10-27 |
| RU2010104631A (ru) | 2011-09-10 |
| JP5502733B2 (ja) | 2014-05-28 |
| US20120040972A1 (en) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
| NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR061867A1 (es) | Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa | |
| MX376743B (es) | Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos | |
| AR050365A1 (es) | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. | |
| AR073622A1 (es) | Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| AR066659A1 (es) | Derivados de espiroindolinona | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| AR070852A1 (es) | Derivados de piridazina y su uso como agentes terapeuticos | |
| UY28578A1 (es) | Derivados de amida | |
| PE20081454A1 (es) | Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor | |
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| PE20070491A1 (es) | Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina | |
| AR067873A1 (es) | Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 | |
| UY29301A1 (es) | Derivados amida | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| ECSP088257A (es) | Derivados de amida | |
| AR062769A1 (es) | Derivados de 5- fenil- nicotilamida | |
| AR064198A1 (es) | Piperidinilamino piridazinas como antagonistas del receptor de dopamina 2 de rapida disociacion. procesos de obtencion y composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |